We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

174 hedge funds and large institutions have $1.86B invested in Celldex Therapeutics in 2024 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 66 increasing their positions, 48 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more call options, than puts

Call options by funds: $24.9M | Put options by funds: $17.1M

38% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 48

2.75% more ownership

Funds ownership: 108.33% → 111.07% (+2.7%)

6% less first-time investments, than exits

New positions opened: 34 | Existing positions closed: 36

1% less funds holding

Funds holding: 176 → 174 (-2)

24% less capital invested

Capital invested by funds: $2.44B → $1.86B (-$579M)

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

Holders
174
Holders Change
-2
Holders Change %
-1.14%
% of All Funds
2.29%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.04%
New
34
Increased
66
Reduced
48
Closed
36
Calls
$24.9M
Puts
$17.1M
Net Calls
+$7.83M
Net Calls Change
-$17.5M

Top Buyers

1
JFG
Jefferies Financial Group
New York
+$64.4M
2
KCM
Kynam Capital Management
New Jersey
+$43.6M
3
DTC
Deep Track Capital
Connecticut
+$41.8M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$25.7M
5
Morgan Stanley
Morgan Stanley
New York
+$24.7M

Top Sellers

1
CC
Commodore Capital
New York
-$55M
2
Jennison Associates
Jennison Associates
New York
-$45M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$31.7M
4
PCH
Polar Capital Holdings
United Kingdom
-$31.4M
5
LGM
Logos Global Management
California
-$30.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
TRCT
101
Tower Research Capital (TRC)
New York
$528K +$277K +10,185 +95%
NIM
102
NEOS Investment Management
Connecticut
$512K -$172K -6,331 -24%
Creative Planning
103
Creative Planning
Kansas
$502K +$137K +5,035 +34%
VOYA Investment Management
104
VOYA Investment Management
Georgia
$492K -$41.8K -1,540 -7%
First Trust Advisors
105
First Trust Advisors
Illinois
$464K -$518K -19,071 -51%
ProShare Advisors
106
ProShare Advisors
Maryland
$460K +$163K +5,986 +49%
Teacher Retirement System of Texas
107
Teacher Retirement System of Texas
Texas
$447K +$76.6K +2,819 +19%
ASRS
108
Arizona State Retirement System
Arizona
$437K +$6.03K +222 +1%
ECM
109
ExodusPoint Capital Management
New York
$436K +$469K +17,244 New
JF
110
Jump Financial
Illinois
$417K +$449K +16,513 New
Zurich Cantonal Bank
111
Zurich Cantonal Bank
Switzerland
$403K +$49.4K +1,819 +13%
N
112
Natixis
France
$399K +$429K +15,800 New
Los Angeles Capital Management
113
Los Angeles Capital Management
California
$390K +$236K +8,683 +129%
State Board of Administration of Florida Retirement System
114
State Board of Administration of Florida Retirement System
Florida
$367K – – –
NRD
115
Nebula Research & Development
New York
$354K +$381K +14,027 New
PFSRSONJ
116
Police & Firemen's Retirement System of New Jersey
New Jersey
$352K +$378K +13,923 New
KK
117
KLP Kapitalforvaltning
Norway
$306K +$329K +12,100 New
EGM
118
Engineers Gate Manager
New York
$290K -$733K -26,997 -70%
BHCM
119
Brevan Howard Capital Management
Jersey
$288K -$174K -6,401 -36%
XT
120
XTX Topco
Cayman Islands
$284K -$942K -34,661 -75%
EFM
121
E Fund Management
China
$273K +$293K +10,785 New
DnB Asset Management
122
DnB Asset Management
Norway
$256K -$1.03K -38 -0.4%
AAA
123
Affinity Asset Advisors
New York
$252K -$3.12M -115,008 -92%
Ameriprise
124
Ameriprise
Minnesota
$251K +$270K +9,944 New
PF
125
Phoenix Financial
Israel
$243K +$261K +9,615 New
3 4
5
6 7

CLDX Hedge Fund Activity: Q4 2024 in Review

174 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q4 2024, worth a combined $1.86B — down 24% from $2.44B a quarter earlier.

Sellers outnumbered buyers: 36 funds closed out of CLDX and 34 opened new positions — a net loss of 2 holders — while 48 trimmed existing stakes and 66 added.

The largest buyer was Jefferies Financial Group, adding an estimated $64.4M. The largest seller was Commodore Capital, exiting entirely with an estimated $55M sold.

  • 174 institutional investors held Celldex Therapeutics (CLDX) as of Q4 2024, down from 176 in Q3 2024.
  • Funds reported $1.86B of Celldex Therapeutics stock for Q4 2024, down 24% quarter-over-quarter.
  • 34 funds opened new Celldex Therapeutics positions in Q4 2024 and 36 closed out, a net change of -2 holders.
  • The largest Celldex Therapeutics buyer in Q4 2024 was Jefferies Financial Group, an estimated $64.4M added.
  • The largest Celldex Therapeutics seller in Q4 2024 was Commodore Capital, an estimated $55M sold.

Based on aggregated 13F filings for Q4 2024.